证券代码：300942 证券简称：易瑞生物 编号：2022-001 投资者关系活动记录表 投资者关系活 特定对象调研 分析师会议 媒体采访 动类别 业绩说明会 新闻发布会 路演活动 现场参观 其他 电话会议 参与单位名称 安信证券股份有限公司、浙商证券股份有限公司 及人员姓名 深圳市易瑞生物技术股份有限公司 | --- | --- | |-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 时间 | 2022 年 1 月 12 日 -13 日 | | 地点 | 公司会议室 | | 上市公司接待 | 董事会秘书兼副总经理：张 ...

证券代码：300942 证券简称：易瑞生物 编号：2022-002 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------|----------------------| | | | | | | | | | | | 投资者关系活 | | □特定对象调研 □分析师会议 □媒体采访 | ☑ | | 动类别 | 业绩说明会 | □新闻发布会 □路演活动□现 | | | | 场参观 | □其他（请文字说明其他活动内容） | | | | | | | | 参与单位名称 及人员姓名 | 线上参与公司 2021 | 年度网上业绩说明会的投资者 | | | 时间 | 2022 年 5 月 17 日 | 15:00-17:00 | | | 地点 | 全景网 " 投资者关系互动平台 | " ...

证券代码：300942 证券简称：易瑞生物 编号：2022-003 投资者关系活动记录表 1 / 4 深圳市易瑞生物技术股份有限公司 | --- | --- | --- | --- | |-------------------------|------------------------------------------------------------|------------------------------------------------------|------------------------| | 投资者关系活 \n动类别 | 特定对象调研 \n 业绩说明会 \n 现场参观 | 分析师会议 \n 新闻发布会 \n 其他 | 媒体采访 \n 路演活动 | | 参与单位名称 及人员姓名 | 国信证券股份有限公司、云棲资本、启峰资本 | | | | 时间 | 2022 年 5 月 26 日 | | | | 地点 | 公司会议室 | | | | 上市公司接待 | 董事会秘书兼副总经理：张煜堃先生 | | | | 人员姓名 | 财务总监：万凯先生 | | | | | 一、公司介绍 公司成立于 2 ...

投资者关系活动记录表 证券代码：300942 证券简称：易瑞生物 编号：2022-004 深圳市易瑞生物技术股份有限公司 | --- | --- | --- | --- | |-----------------------|----------------------------------|------------------------------------------------------------|------------------------------------| | | | | | | 投资者关系活 | 特定对象调研 | 分析师会议 | 媒体采访 | | 动类别 | 业绩说明会 | 新闻发布会 | 路演活动 | | | 现场参观 | 其他 2022 | 年深圳辖区上市公司投资 | | | 者集体接待日活动 | | | | 参与单位名称 | 参与公司 2022 | 年深圳辖区上市公司投资者集体接待日活动的投 | | | 及人员姓名 | 资者 | | | | | | | | | 时间 | 2022 年 11 月 9 日下午 | 16:30-17:30 | | | 地点 | "全景路演"（ ...

证券代码：300942 证券简称：易瑞生物 公告编号：2022-098 深圳市易瑞生物技术股份有限公司 关于参加深圳辖区上市公司 2022 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，深圳市易瑞生物技术股份有限公司 （以下简称"公司"）将参加由深圳证监局指导、深圳上市公司协会与深圳市全 景网络有限公司联合举办的"2022 年深圳辖区上市公司投资者集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2022 年 11 月 9 日（周三）16:30-17:30。 届时公司董事会秘书、财务总监万凯先生将在线通过网络文字交流形式与投 资者进行沟通交流，欢迎广大投资者踊跃参与！ 特此公告。 深圳市易瑞生物技术股份有限公司 董事会 2022 年 11 月 3 日 ...

深圳市易瑞生物技术股份有限公司 2022 年第三季度报告 证券代码：300942 证券简称：易瑞生物 公告编号：2022-094 深圳市易瑞生物技术股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 上年同期增减 | | 营业收入（元） | 97,425,576.62 | -3.14% | 572,094,603.75 | 32.71% ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥474,669,027.13, representing a 43.63% increase compared to ¥330,490,442.36 in the same period last year[21]. - The net profit attributable to shareholders decreased by 7.28% to ¥151,413,759.86 from ¥163,308,712.30 year-on-year[21]. - The net cash flow from operating activities significantly dropped by 91.18% to ¥16,473,397.52, down from ¥186,855,394.45 in the previous year[21]. - The total assets increased by 10.52% to ¥1,273,731,841.06 compared to ¥1,152,520,292.55 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 8.30% to ¥1,023,183,519.34 from ¥944,762,745.98 at the end of the previous year[21]. - The basic earnings per share decreased by 9.52% to ¥0.38 from ¥0.42 in the same period last year[21]. - The weighted average return on net assets fell to 14.88% from 21.93% year-on-year, a decrease of 7.05%[21]. - The company's revenue for the reporting period reached ¥474,669,027.13, representing a 43.63% increase compared to ¥330,490,442.36 in the previous year, primarily driven by growth in the in vitro diagnostic business[91]. - The cost of sales increased by 125.03% to ¥168,126,597.67, up from ¥74,712,530.84, due to rising key raw material and labor costs associated with increased revenue[91]. Research and Development - The company invested 40.73 million yuan in R&D, a year-on-year increase of 34.94%, focusing on core antigen-antibody research and product certification[37]. - The company has maintained high R&D investment, focusing on antigen-antibody research and development, resulting in a diverse product output[78]. - The company has a strong capability for new product development, leveraging its proprietary antigen and antibody preparation technology to create diverse product offerings[84]. - The company has developed a rapid solid-phase extraction (SPE) technology that simplifies the sample preparation process from five steps to two, enhancing detection efficiency and accuracy[86]. - The company emphasizes the importance of R&D innovation and has established collaborations with research institutions to enhance its technological capabilities[130]. Market and Product Development - The company focuses on rapid detection technology applied in food safety and in vitro diagnostics, with no significant changes in its main business during the reporting period[30]. - The main products include rapid detection reagents and instruments for food safety, as well as various POCT products for clinical diagnostics[30]. - The company has developed a series of products for drug detection, thyroid function testing, cardiovascular disease detection, and more, utilizing multiple R&D platforms[31]. - The company is positioned to capture market share through its core technology advantages in antigen-antibody raw material development[56]. - The company achieved significant growth in overseas sales, enhancing product penetration in international markets through effective marketing and partnerships with international dairy groups and agricultural departments[58]. - The POCT (Point of Care Testing) business is in a high-growth phase, with the market expected to expand rapidly due to increasing demand and stable technology[59]. - The global POCT market size was approximately $29.5 billion in 2020, projected to reach $50.6 billion by 2025, with a compound annual growth rate (CAGR) of about 11.4%[69]. - The domestic food safety rapid testing market is expected to grow from approximately 19.68 billion yuan in 2016 to 91.75 billion yuan by 2022, with a CAGR of 25.24%[67]. Corporate Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management[3]. - All directors attended the board meeting to review the report, ensuring comprehensive oversight[4]. - The report includes a section on corporate governance and social responsibility, highlighting the company's commitment to ethical practices[5]. - The company has established a governance structure that includes a shareholders' meeting, board of directors, independent directors, and a supervisory board to protect shareholder rights[149]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[147]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[147]. - The company has implemented measures to comply with environmental regulations and has not faced any violations during the reporting period[147]. Financial Management and Fundraising - The total fundraising amount reached RMB 175.35 million after deducting various issuance costs[115]. - Cumulative investment of RMB 24.51 million from the fundraising as of June 30, 2022[115]. - The company temporarily supplemented working capital with RMB 65 million from the fundraising[115]. - The balance of the special account for fundraising was RMB 1.52 million as of June 30, 2022[115]. - The company has signed a tripartite supervision agreement with banks and sponsors for the management of fundraising[115]. - The company has reported a total of RMB 373.4 million in entrusted financial management, with RMB 284 million from self-owned funds and RMB 88.4 million from raised funds[122]. Risks and Challenges - The company faces risks related to the dependency on imported raw materials, particularly nitrocellulose membranes, which are crucial for its products[132]. - The company acknowledges the uncertainty and unsustainability of revenue growth driven by COVID-19 testing products, which may be affected by global pandemic conditions[131]. - The company has experienced rapid business expansion, particularly in in vitro diagnostics and animal diagnostics, which has increased management risks due to the need for enhanced operational capabilities[133]. - The company plans to strengthen its corporate culture and management systems to mitigate risks associated with rapid growth[133]. Shareholder Information - The company did not distribute cash dividends or issue bonus shares for the half-year period[141]. - The company approved a stock incentive plan in 2021, granting 6.55 million restricted shares at a price of 16.22 CNY per share to 55 eligible participants[143]. - The company held three temporary shareholder meetings in 2022, with participation rates of 71.89%, 74.93%, and 74.95% respectively[138]. - The total number of common shareholders at the end of the reporting period was 18,037[187]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[192]. Strategic Initiatives - The company is actively expanding its international market presence and enhancing its operational management to mitigate risks from potential policy changes[128]. - The company aims to maintain global health as its mission, focusing on food and drug safety, in vitro diagnostics, and public safety[148]. - The company has established a wholly-owned subsidiary, enhancing its operational capabilities and market presence[175]. - The company has engaged in partnerships with professional investment institutions to explore investment opportunities, indicating a strategic focus on growth[176].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 300 million RMB in 2021, representing a growth of 25% year-over-year [16]. - The company's operating revenue for 2021 was CNY 597,539,623.17, representing a 131.20% increase compared to CNY 258,455,671.51 in 2020 [20]. - The net profit attributable to shareholders for 2021 was CNY 236,507,393.22, a significant increase of 261.38% from CNY 65,445,058.17 in 2020 [20]. - The net profit after deducting non-recurring gains and losses was CNY 213,698,482.19, up 275.71% from CNY 56,877,824.49 in 2020 [20]. - The net cash flow from operating activities reached CNY 255,424,985.52, marking a 300.39% increase from CNY 63,793,860.76 in 2020 [20]. - The company's basic earnings per share for 2021 was CNY 0.6, reflecting a 233.33% increase from CNY 0.18 in 2020 [20]. - The weighted average return on equity for 2021 was 29.41%, up from 12.32% in 2020, indicating improved profitability [20]. - The company achieved a revenue of 597.54 million yuan, representing a year-on-year growth of 131.20% [69]. - The net profit attributable to shareholders reached 236.51 million yuan, an increase of 261.38% compared to the previous year [69]. - The revenue from food safety rapid detection business was 182.53 million yuan, showing a slight growth of 1.38% year-on-year [70]. - The revenue from in vitro diagnostic rapid testing (POCT) business surged to 415.01 million yuan, a significant increase of 429.27% year-on-year, driven by sales of COVID-19 antigen testing solutions [72]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 2.49 RMB per 10 shares to all shareholders, based on a total of 400,860,000 shares [5]. Market Expansion and Strategy - The company provided a positive outlook for 2022, projecting a revenue growth of 30% driven by new product launches and market expansion efforts [16]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share within the next two years [16]. - A strategic acquisition of a local biotech firm was announced, expected to enhance the company's product portfolio and increase market competitiveness [16]. - The company is actively pursuing partnerships with international distributors to broaden its global reach and improve sales channels [16]. - The company aims to deepen its focus on food safety rapid testing and provide customized comprehensive solutions to achieve international market growth [141]. - The company plans to expand its POCT business and develop a product line focused on infectious disease detection, targeting key overseas markets [142]. Research and Development - Investment in R&D increased by 15%, focusing on the development of new diagnostic technologies and enhancing existing product lines [16]. - The company invested 72.43 million yuan in R&D, marking a 79.01% increase from the previous year [74]. - The company launched over 110 new products in the food safety sector, including a multi-residue rapid test strip for detecting 16 pesticide residues [77]. - The company has developed over 120 self-produced antigens and 140 self-produced antibodies, achieving a high level of self-sufficiency in key raw materials for rapid testing products [60]. - The company has been recognized for its contributions to scientific advancements, receiving multiple awards for its R&D efforts [183]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and strategies, as outlined in the management discussion section [5]. - The report includes a detailed analysis of potential risk factors that the company may face in the future [5]. - The company faces risks related to policy changes and industry regulations, which could impact its operational performance, and it is committed to adapting to these changes [147]. - The company recognizes the uncertainty and unsustainability of revenue growth driven by the COVID-19 pandemic and is preparing for potential market fluctuations [150]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights [157]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a diverse range of expertise [159]. - The company maintains independence from its controlling shareholders, with no significant related party transactions or competition [165]. - The company has implemented a robust information disclosure system to ensure transparency and timely communication with investors [162]. - The company is committed to enhancing its internal control and governance practices as indicated in its self-evaluation report [192]. Sustainability and Social Responsibility - The management emphasized a commitment to sustainability, aiming to reduce operational costs by 10% through improved efficiency measures [16]. - The company is committed to balancing the interests of stakeholders, including shareholders, employees, and the community, to promote sustainable development [163]. Employee and Management Structure - The total number of employees at the end of the reporting period is 650, with 382 in the parent company and 268 in major subsidiaries [200]. - The company has a diverse management team with members having extensive experience in various industries, including finance and biotechnology [184]. - The educational background of employees includes 6 with a doctorate, 26 with a master's degree, 240 with a bachelor's degree, and 378 with an associate degree or below [200]. Product Development and Innovation - The company focuses on rapid testing technology applied in food safety and in vitro diagnostics, with major business segments being food safety rapid testing and POCT (Point of Care Testing) [40]. - The company has established a comprehensive quality management system, holding multiple certifications including ISO13485:2016 and ISO9001:2015 [48]. - The company has developed new products for animal testing, including detection methods for various diseases in livestock [78]. - The company has successfully developed diagnostic products for animal diseases and established production lines, with plans to accelerate the industrialization of these products [143].

Financial Performance - The company's revenue for Q1 2022 reached ¥294,001,215.63, representing a 100.11% increase compared to ¥146,917,926.77 in the same period last year[4] - Net profit attributable to shareholders was ¥114,128,972.49, a 30.27% increase from ¥87,610,355.16 year-over-year[4] - Basic and diluted earnings per share increased by 21.74% to ¥0.28 from ¥0.23[4] - The net profit after deducting non-recurring gains and losses was RMB 108 million, up 36.32% year-on-year[15] - The company’s total operating revenue reached CNY 294,001,215.63 for the current period, a significant increase from CNY 146,917,926.77 in the previous period, representing a growth of approximately 100%[21] - The net profit for Q1 2022 was CNY 114,098,297.86, an increase of 30.3% compared to CNY 87,599,429.10 in Q1 2021[22] - The total comprehensive income for Q1 2022 was CNY 114,017,886.19, compared to CNY 86,965,485.64 in the same period last year[22] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥51,177,229.38, a decline of 152.13% compared to ¥98,176,735.85 in the previous year[4] - The company's cash and cash equivalents decreased to CNY 306,951,385.94 from CNY 342,211,180.47 at the beginning of the year, a decline of approximately 10.2%[17] - The cash flow from operating activities showed a net outflow of CNY -51,177,229.38, compared to a net inflow of CNY 98,176,735.85 in the same period last year[24] - The company reported cash and cash equivalents at the end of Q1 2022 amounting to CNY 303,982,289.69, down from CNY 464,332,177.81 at the end of Q1 2021[26] - The company generated CNY 437,566,466.36 in cash inflow from investment activities, significantly higher than CNY 206,207,905.11 in the previous year[24] - The net cash flow from investment activities was CNY 15,956,035.85, recovering from a net outflow of CNY -190,871,815.39 in Q1 2021[26] Assets and Liabilities - Total assets grew by 16.17% to ¥1,338,832,695.50 from ¥1,152,520,292.55 at the end of the previous year[4] - The total liabilities increased to CNY 264,902,209.87 from CNY 205,940,193.12, representing a rise of approximately 28.6%[19] - The company's retained earnings rose to CNY 466,114,874.37 from CNY 351,985,901.88, an increase of about 32.4%[20] - Accounts receivable increased significantly to CNY 201,003,768.99 from CNY 97,051,672.70, reflecting a growth of about 106.5%[17] - The inventory level rose to CNY 119,298,357.46 from CNY 93,859,305.88, marking an increase of approximately 27.1%[18] Research and Development - Research and development expenses increased by 45.98% to ¥15,605,979.98 as the company focused on industry trends[8] - The company continues to increase R&D investment to enhance product development and intellectual property protection[15] - The company added 7 new authorized patents during the reporting period, including 3 domestic invention patents and 2 overseas patents[15] Business Expansion and Partnerships - The company expanded its POCT business sales channels through a partnership with Hong Kong Xiangda Biological[15] - The company established a wholly-owned subsidiary, Aido Biology, to enhance product innovation and accelerate the acquisition of new veterinary drug certifications[16] - The company has partnered with professional investment institutions to establish Zhengrui Investment, aimed at enhancing the overall competitiveness and expanding the industrial chain[16] Market and Regulatory Environment - The demand for COVID-19 testing products remains strong due to the ongoing impact of the Omicron variant[15] - The company is committed to monitoring the pandemic situation to contribute to domestic and international epidemic prevention efforts[15] - The company obtained domestic medical device registration for its COVID-19 antigen test kit in March 2022[15] Operating Costs - The gross profit margin was impacted by a 311.55% increase in operating costs, which reached ¥96,408,256.89[8] - The total operating costs for the current period were CNY 155,220,845.49, compared to CNY 57,064,106.14 in the previous period, indicating an increase of about 172%[21] Shareholder Information - The company’s major shareholder, Shenzhen Yirui Holdings, holds 37.67% of the shares, with 151 million shares pledged[10]

证券代码：300942 证券简称：易瑞生物 公告编号：2021-097 深圳市易瑞生物技术股份有限公司 关于参加 2021 深圳辖区"沟通传递价值，交流创造良好生态" 上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，深圳市易瑞生物技术股份有限公司 （以下简称"公司"）将参加由深圳上市公司协会、深圳市全景网络有限公司共 同举办的"沟通传递价值，交流创造良好生态"——2021 深圳辖区上市公司投 资者网上集体接待日活动，现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net/） 或关注微信公众号：全景财经，参与公司本次投资者集体接待日活动，活动时间 为 2021 年 11 月 30 日 14:00 至 17:00。 届时公司的董事会秘书张煜堃先生和财务总监王广生先生将通过网络文字 交流形式与投资者进行沟通。 欢迎广大投资者积极参与。 特此公告。 深圳市易瑞生物技术 ...